Skye Bioscience (SKYE) Cash from Financing Activities (2013 - 2026)
Skye Bioscience (SKYE) posted quarterly Cash from Financing Activities of -$71525.0 for Q1 2026, down 726.7% quarter-over-quarter from $11413.0 in Q4 2025.
Skye Bioscience (SKYE) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Cash from Financing Activities for 13 consecutive years, with -$71525.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to -$71525.0; the TTM figure through Mar 2026 stood at -$41954.0 (up 97.99% YoY), while the FY2025 annual figure was $29571.0, down 99.96% from the prior year.
- Cash from Financing Activities declined to -$71525.0 in Q1 2026 per SKYE's latest filing, from $11413.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $85.7 million in Q1 2024 and bottomed at -$2.1 million in Q2 2024.
- Historically, Cash from Financing Activities has averaged $7.1 million across 5 years, with a median of -$33980.5 in 2023.
- On a YoY basis, Cash from Financing Activities climbed as much as 189149.41% in 2024 and fell as far as 1598.41% in 2024.
- Skye Bioscience's Cash from Financing Activities stood at $34161.0 in 2022, then sank by 166.32% to -$22654.0 in 2023, then surged by 124.8% to $5618.0 in 2024, then soared by 103.15% to $11413.0 in 2025, then plunged by 726.7% to -$71525.0 in 2026.
- Business Quant data shows SKYE's Cash from Financing Activities at -$71525.0 in Q1 2026, $11413.0 in Q4 2025, and $18158.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | -101,014.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -71,525.00 |
| Mar 31, 2026 | -71,525.00 |
| Dec 31, 2025 | 11,413.00 |
| Dec 31, 2025 | 11,413.00 |
| Jun 30, 2025 | 18,158.00 |
| Jun 30, 2025 | 18,158.00 |
| Dec 31, 2024 | 5,618.00 |
| Dec 31, 2024 | 5,618.00 |
| Jun 30, 2024 | -2.10 Mn |
| Jun 30, 2024 | -2.10 Mn |
| Mar 31, 2024 | 85.65 Mn |
| Mar 31, 2024 | 85.65 Mn |
| Dec 31, 2023 | -22,654.00 |
| Dec 31, 2023 | -22,654.00 |
| Sep 30, 2023 | 16.63 Mn |
| Sep 30, 2023 | 16.63 Mn |
| Jun 30, 2023 | -123,413.00 |
| Jun 30, 2023 | -123,413.00 |
| Mar 31, 2023 | -45,307.00 |
| Mar 31, 2023 | -45,307.00 |